Skip to content
CDC

Data based on the current 2023 baseline can be found here. Previous data based on the 2017/2018 baselines are archived on this page, and no additional data will be added.

Antibiotic Use

Inpatient Antibiotic Use (2017/2018 Baseline)

ADULT: Number of Facilities with the All Antibacterial SAAR Statistically Significantly > 1.0

985 / 2302 (42.8%)

Facilities in 2023

PEDIATRIC: Number of Facilities with the All Antibacterial SAAR Statistically Significantly > 1.0

106 / 404 (26.2%)

Facilities in 2023

NEONATAL: Number of Facilities with the All Antibacterial SAAR Statistically Significantly > 1.0

216 / 800 (27.0%)

Facilities in 2023

Inpatient Antibiotic Use

The Standardized Antimicrobial Administration Ratio (SAAR) is a risk-adjusted summary measure of antimicrobial use available to acute care hospitals participating in the National Healthcare Safety Network (NHSN) Antimicrobial Use (AU) Option. Hospitals can use the SAAR to track AU, compare their AU to a national benchmark, and assess the impact of interventions aimed at improving prescribing practices.

Baseline Year
2017/2018
Years Included
2021 - 2023
Resources

Geographic Location

Standardized Antimicrobial Administration Ratio (SAAR) values vary across U.S. states and territories. Hospitals can use this risk-adjusted summary measure of AU to compare their AU to their state's distribution to help identify meaningful SAAR targets.

Percentage of Eligible Facilities reporting SAAR Data by State

This map displays the percentage of eligible facilities reporting SAAR data, by state, for the select SAAR population, in 2023.

To view State Profile data, hover and click on desired State.

For additional detail on eligible facility definitions, please see footnotes.

Percentage of Eligible Facilities reporting Adult SAAR Data by State in 2023

SAAR Data by State map

This map displays 2023 median SAAR values for all SAAR agent categories and SAAR populations, by state and select territories.

To view State Profile data, hover and click on desired State.

For specific SAAR agent category names, please see footnotes below.

For additional SAAR distribution data, please see “View Data” tab.

For more information on insufficient data, please see footnotes below.

SAAR Data by State: All Antibacterial Agents for Adults

SAAR Data by State List

This graphic displays 2023 median SAAR values for all SAAR agent categories and SAAR populations, by state and select territories.

For specific SAAR agent category names, please see footnotes below.

States without results shown did not have sufficient data in 2023. For more information on insufficient data, please see footnotes below.

SAAR Data by State reporting All Antibacterial Agents for Adults in 2023

Footnotes

  • The National Healthcare Safety Network (NHSN) Antimicrobial Use (AU) Option Report summarizes data reported to NHSN from 2021 - 2023 for adult, pediatric, and neonatal data.
  • Only patient care locations reporting 9 months or more in 2021 - 2023 were included in analyses. Analyses were limited to SAAR locations reporting from eligible facility types.
  • Eligible adult: any critical access, general acute care, military, oncology, surgical, veteran affairs, women's or women and children's facilities actively participating in NHSN, with a recent annual hospital survey and at least one active adult SAAR location mapped in NHSN to that facility.
  • Eligible pediatric: any children's, general acute care, military or women and children's facilities actively participating in NHSN, with a recent annual hospital survey and at least one active pediatric SAAR location mapped in NHSN to that facility.
  • Eligible neonatal: any children's, general acute care, military, women's or women and children's facilities actively participating in NHSN, with a recent annual hospital survey and at least one active neonatal SAAR location mapped in NHSN to that facility.
  • More information regarding locations and facilities eligible to receive SAARs can be found in the SAAR guide. Survey data were used for risk adjustment, when possible.
  • Data should not be compared year-by-year.
  • For states with fewer than 10 facilities, percentile data is omitted due to insufficient data. For states with 10-19 facilities, only median values are shown. For states with ≥20 facilities, full distributions are displayed.
  • SAAR agent categories:
    • Broad Spectrum Hospital-Onset - Broad spectrum antibacterial agents predominantly used for hospital-onset infections
    • Broad Spectrum Community-Acquired - Broad spectrum antibacterial agents predominantly used for community-acquired infections
    • Gram-Positive - Antibacterial agents predominantly used for resistant gram-positive infections (e.g., MRSA)
    • Narrow Spectrum Beta-Lactam - Narrow spectrum beta-lactam agents
    • Clostridioides difficile - Antibacterial agents posing the highest risk for CDI
    • Antifungal - Antifungal agents predominantly used for invasive candidiasis
    • Azithromycin - Azithromycin
    • Vancomycin - Vancomycin predominantly used for treatment of late-onset sepsis
    • Cephalosporins - Third generation Cephalosporins
    • Ampicillin - Ampicillin predominantly used for treatment of early-onset sepsis
    • Aminoglycosides - Aminoglycosides predominantly used for treatment of early-onset and late-onset sepsis
    • Fluconazole - Fluconazole predominantly used for candidiasis